Digestive Diseases and Sciences

, Volume 52, Issue 5, pp 1168–1176 | Cite as

Reasons Why Patients Infected with Chronic Hepatitis C Virus Choose to Defer Treatment: Do They Alter Their Decision with Time?

Original Research

Abstract

This study was designed to determine the percentage of treatment-naïve patients infected with chronic hepatitis C virus who make an informed choice to forego (defer) treatment with pegylated interferon regimens in the absence of any medical, psychosocial, or other contraindications, and to reassess their decision by using a questionnaire at least 1 year later. Patient charts dating from 2001 were retrieved and retrospectively analyzed for the following data: patient age, gender, race, hepatitis C viral load, genotype, liver biopsy results, hepatic imaging results, peak alanine aminotransferase (ALT) levels, comorbid conditions, source of infection, estimated duration of infection, and reasons given by the patient for declining pegylated interferon-based treatment at the time of their consultation. A questionnaire survey sought to determine their satisfaction with their initial decision. Of 446 patient charts reviewed, 280 patients were treatment-naïve and were judged to have no contraindications to receiving interferon-based therapy. Of these, 115 (41%) opted to defer treatment and are the subject of this analysis. Women declining therapy outnumbered men by approximately 3 to 2. Middle-aged patients (45–55 years) were most likely to choose expectant therapy compared with older or younger individuals. The proportion of African American patients who deferred therapy (48%) was higher than non-African American patients (36.6%). More than 90% of the patients choosing to be followed were genotype 1. Peak ALT values were normal in 37% and <2X upper limits of normal (ULN) in another 40%. The estimated duration of chronic hepatitis C infection was >16 years in approximately three-quarters of individuals. The most common source of their infection was intravenous drug use followed by transfusion-related. The most common reason for opting not to receive treatment, given by nearly two-thirds of patients, was the asymptomatic nature of their infection coupled with their concern about side effects of the medications. Approximately 10% had unfavorable social situations, including a lack of support or health insurance, that precluded receiving therapy (despite the availability of indigent care programs offered by the pharmaceutical manufacturers). Only five patients (4.3%) cited doubts about efficacy as the main reason that they did not want to be treated. The questionnaire survey at 1 year found that 79% of the patients confirmed their ongoing satisfaction with their initial decision to decline treatment, and another 10.6% indicated that they were still “moderately satisfied” with their decision and unlikely to change it in the near-future. Only six patients (7%) voiced their current dissatisfaction with expectant management and expressed the desire to have a follow-up discussion about treatment options. Of the remaining three patients (3.5%), two had already started treatment and one was deceased (of non-liver–related causes). A significant proportion of patients infected with hepatitis C virus who are otherwise eligible for therapy opt to defer treatment (41% overall in our series, with African American patients deferring in a higher proportion than non-African American patients). Nearly all of our patients were genotype 1 with clinically and histologically mild hepatitis of reasonably long duration. Our questionnaire survey found that most remained satisfied with their decision to defer treatment at the present time. Few patients cited a perceived low rate of efficacy of pegylated interferon and ribavirin therapy as the principal reason that they chose not to initiate treatment.

Keywords

Chronic hepatitis C Deferred treatment Patient satisfaction 

References

  1. 1.
    Fried MW, Hadziyannis SJ (2004) Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 24(Suppl 2):47–54PubMedCrossRefGoogle Scholar
  2. 2.
    Ferenci P (2004) Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24(Suppl 2):25–31PubMedCrossRefGoogle Scholar
  3. 3.
    Pawlotsky JM (2006) Therapy of hepatitis C: From empiricism to eradication. Hepatology 43(S1):S207–S220PubMedCrossRefGoogle Scholar
  4. 4.
    Anonymous (2002) National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 36(Suppl 1):S3–S20Google Scholar
  5. 5.
    Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 1147–1171Google Scholar
  6. 6.
    Wang P, Yi Q, Scully L (2003) Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists. Can J Gastroenterol 17:183–186PubMedGoogle Scholar
  7. 7.
    Ward RP, Kugelmas M, Libsch KD (2004) Management of hepatitis C: evaluating suitability for drug therapy. Am Fam Physician 69:1429–1436PubMedGoogle Scholar
  8. 8.
    Herrine SK (2002) Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 136:747–757PubMedGoogle Scholar
  9. 9.
    Reddy KR (2004) Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated. Am J Gastroenterol 99:973–975PubMedCrossRefGoogle Scholar
  10. 10.
    Koff JM, Younossi Z (2004) Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated. Am J Gastroenterol 99: 972–973PubMedCrossRefGoogle Scholar
  11. 11.
    Thomas DL, Seeff LB (2005) Natural history of hepatitis C. Clin Liver Dis 9:383–398PubMedCrossRefGoogle Scholar
  12. 12.
    Poynard T, Ratziu V, Charlotte F, et al. (2001) Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34:730–739PubMedCrossRefGoogle Scholar
  13. 13.
    Ryder SD on behalf of the Trent Hepatitis C Study Group (2004) Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53:451–455PubMedCrossRefGoogle Scholar
  14. 14.
    Wong JB, Koff RS for the International Hepatitis Interventional Therapy Group (2000) Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 133:665–675PubMedGoogle Scholar
  15. 15.
    Afdhal NH (2004) The natural history of hepatitis C. Semin Liver Dis 24(Suppl 2):3–8PubMedCrossRefGoogle Scholar
  16. 16.
    Bini EJ, Brau N, Currie S, et al. (2005) Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772–1179PubMedCrossRefGoogle Scholar
  17. 17.
    Cheung RC, Currie S, Shen H, et al. (2005) Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 100:2186–2193PubMedCrossRefGoogle Scholar
  18. 18.
    Falck-Ytter Y, Kale H, Mullen KD, et al. (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288–292PubMedGoogle Scholar
  19. 19.
    Cawthorne CH, Rudat KR, Burton MS, et al. (2002) Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 97:149–155PubMedCrossRefGoogle Scholar
  20. 20.
    De Bie J, Robaeys G, Buntinx F (2005) Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): guidelines for clinical practice. Acta Gastroenterol Belg 68:68–80PubMedGoogle Scholar
  21. 21.
    Lehman CL, Cheung RC (2002) Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 97:2640–2646PubMedCrossRefGoogle Scholar
  22. 22.
    Muir AJ, Provenzale D (2002) A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 34:268–271PubMedCrossRefGoogle Scholar
  23. 23.
    Rowan PJ, Tabasi S, Abdul-Latif M, et al. (2004) Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 38:530–534PubMedCrossRefGoogle Scholar
  24. 24.
    Butt AA, Wagener M, Shakil AO, et al. (2005) Reasons for nontreatment in hepatitis C in veterans in care. J Viral Hepatol 12:81–85CrossRefGoogle Scholar
  25. 25.
    Tavakoli-Tabasi S, Rowan P, Abdul-Latif M, et al. (2005) Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study. Aliment Pharmacol Ther 21:235–242PubMedCrossRefGoogle Scholar
  26. 26.
    Nguyen HA, Miller AI, Dieperink E, et al. (2002) Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 97:1813–1820PubMedCrossRefGoogle Scholar
  27. 27.
    Fireman M, Indest DW, Blackwell A, et al. (2005) Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis 40(Suppl 5):S286–S291PubMedCrossRefGoogle Scholar
  28. 28.
    Schaefer M, Schmidt F, Folwaczny C, et al. (2003) Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37:443–451PubMedCrossRefGoogle Scholar
  29. 29.
    Allen SA, Spaulding AC, Osei AM, et al. (2006) Treatment of hepatitis C in a state correctional facility. Ann Intern Med 138:187–190Google Scholar
  30. 30.
    Geppert CMA, Arora S (2005) Ethical issues in the treatment of hepatitis C. Clin Gastroenterol Hepatol 3:937–944PubMedCrossRefGoogle Scholar
  31. 31.
    Srivastava S, Bertagnolli M, Lewis JH (2005) Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc 97:1703–1707PubMedGoogle Scholar
  32. 32.
    Gallegos-Orozco JF, Loaeza-del Castillo A, Fuentes AP, et al. (2005) Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin. Liver Int 25:91–95PubMedCrossRefGoogle Scholar
  33. 33.
    Carlsson T, Reichard O, Norkrans G, et al. (2005) Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepatol 12:473–480CrossRefGoogle Scholar
  34. 34.
    Knodell RG, Ishak KG, Black WC, et al. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435PubMedCrossRefGoogle Scholar
  35. 35.
    Ishak KG (2000) Pathologic features of chronic hepatitis: a review and update. Am J Clin Pathol 113:40–55PubMedCrossRefGoogle Scholar
  36. 36.
    Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36(Suppl 1):S237–S244PubMedCrossRefGoogle Scholar
  37. 37.
    Piton A, Poynard T, Imbert-Bismut F, et al. (1998) Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27:1213–1219PubMedCrossRefGoogle Scholar
  38. 38.
    Elinav E, Ben-Dov IZ, Ackerman E, et al. (2005) Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol 100:2201–2204PubMedCrossRefGoogle Scholar
  39. 39.
    Andriulli A, Persico M, Iacobellis A, et al. (2004) Treatment of patients with HCV infection with or without liver biopsy. J Viral Hepatol 11:536–542CrossRefGoogle Scholar
  40. 40.
    Shiffman ML (2004) Hepatitis C with normal liver enzymes: to treat or not to treat. A balancing view: a decision to be shared with patients. Am J Gastroenterol 99:975–976PubMedCrossRefGoogle Scholar
  41. 41.
    Alberti A, Benvegnu L, Boccato S, et al. (2004) Natural history of initially mild chronic hepatitis C. Dig Liver Dis 36:646–654PubMedCrossRefGoogle Scholar
  42. 42.
    Poynard T, Imbert-Bismut F, Munteanu M (2004) Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3:8PubMedCrossRefGoogle Scholar
  43. 43.
    Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20:17–35PubMedCrossRefGoogle Scholar
  44. 44.
    Poynard T, Ratziu V, Benmanov Y, et al. (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47–55PubMedCrossRefGoogle Scholar
  45. 45.
    Hui CK, Belaye T, Montegrande K, Wright TL (2003) A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 38:511–517PubMedCrossRefGoogle Scholar
  46. 46.
    Reddy KR, Hoofnagle JH, Tong MJ, et al. (1999) Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30:787–793PubMedCrossRefGoogle Scholar
  47. 47.
    Pyrsopoulos N, Jeffers L (2005) Chronic hepatitis C in African Americans. Clin Liver Dis 9:427–438PubMedCrossRefGoogle Scholar
  48. 48.
    Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. Atlantic Coast Hepatitis Treatment Group. N Engl J Med 350:2265–2271PubMedCrossRefGoogle Scholar
  49. 49.
    McHutchinson JG, Poynard T, Pianko S, et al. (2000) The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Intervention Therapy Group. Gastroenterology 119:1317–1323CrossRefGoogle Scholar
  50. 50.
    Jensen DM, Cotler SJ, Lam H, et al. (2004) A comparison of hepatitis C treatment and outcomes at academic, private and Veterans’ Affairs treatment centres. Aliment Pharmacol Ther 19:69–77PubMedCrossRefGoogle Scholar
  51. 51.
    Bellentani S, Pozzato G, Saccoccio G, et al. (1999) Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 44:874–880PubMedCrossRefGoogle Scholar
  52. 52.
    Seeff LB, Miller RN, Rabkin CS, et al. (2000) 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132:105–111PubMedGoogle Scholar
  53. 53.
    Minola E, Prati D, Suter F (2002) Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 99:4588–4591PubMedCrossRefGoogle Scholar
  54. 54.
    Seeff LB, Hollinger FB, Alter HJ (2001) Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 33:455–463PubMedCrossRefGoogle Scholar
  55. 55.
    Dev A, Patel K, McHutchison JG (2004) New therapies for chronic hepatitis C virus infection. Curr Gastroenterol Rep 6:77–86PubMedGoogle Scholar
  56. 56.
    Glenn JS (2005) Novel therapies for hepatitis C virus based on lessons from virology. Clin Gastroenterol Hepatol 3(Suppl 2):S86–S88PubMedCrossRefGoogle Scholar
  57. 57.
    Keeffe EB (2005) Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol 3(Suppl 2):S102–S105PubMedCrossRefGoogle Scholar
  58. 58.
    Grant WC, Jhaveri RR, McHutchinson JG, Schulman KA, Kauf TL (2005) Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 42:1406–1413PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Gastroenterology, Hepatology SectionGeorgetown University Medical CenterWashingtonUSA
  2. 2.Professor of Medicine, Director of HepatologyGeorgetown University Medical CenterWashingtonUSA

Personalised recommendations